Clinical significance of vimentin-positive gastric cancer cells

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5239-5244

  Fuyuhiro, Yuhiko ^a   Yashiro, Masakazu ^a   Noda, Satoru ^a   Kashiwagi, Shinichiro ^a   Matsuoka, Junko ^a   Doi, Yosuke ^a   Kato, Yukihiro ^a   Kubo, Naoshi ^a   Ohira, Masaichi ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric carcinoma cells; Lymph node metastasis; Prognosis; Scirrhous type; Vimentin

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; VIMENTIN;

ARTICLE; CANCER CELL; CANCER STAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER;

ADENOCARCINOMA; CARCINOEMBRYONIC ANTIGEN; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LYMPHATIC METASTASIS; MICROSCOPY, FLUORESCENCE; PARAFFIN EMBEDDING; STOMACH NEOPLASMS; SURVIVAL RATE; VIMENTIN;

EID: 78751564906     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Franke WW, Schmid E, Osborn M and Weber K: Different intermediate-sized filaments distinguished by immunofluorescence microscopy. Proc Natl Acad Sci USA 75(10): 5034-5038, 1978. (Pubitemid 9056332)
2. Franke WW, Grund C, Kuhn C, Jackson BW and Illmensee K: Formation of cytoskeletal elements during mouse embryogenesis. Ill, Primary mesenchymal cells and the first appearance of vimentin filaments. Differentiation 23(1): 43-59, 1982.
3. Greenburg G and Hay ED: Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 95(1): 333-339, 1982.
4. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6): 442-454, 2002.
5. Iwatsuki H, Sasaki K, Suda M and Itano C: Vimentin intermediate filament protein as differentiation marker of optic vesicle epithelium in the chick embryo. Acta Histochem 101(4): 369-382, 1999.
6. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P and Foidart JM: Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 63(10): 2658-2664, 2003.
7. Korsching E, Packeisen J, Liedtke C, Hungermann D, Wulfing P, van Diest PJ, Brandt B, Boecker W and Buerger H: The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 206(4): 451-457, 2005.
8. Ben-Ze'ev A and Raz A: Relationship between the organization and synthesis of vimentin and the metastatic capability of B16 melanoma cells. Cancer Res 45(6): 2632-2641, 1985.
9. Domagala W, Striker G, Szadowska A, Dukowicz A, Harezga B and Osborn M: p53 protein and vimentin in invasive ductal NOS breast carcinoma - relationship with survival and sites of metastases. Eur J Cancer 30A(10): 1527-1534, 1994.
10. Hendrix MJ, Seftor EA, Seftor RE and Trevor KT: Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 150(2): 483-495, 1997.
11. Gilles C, Polette M, Piette J, Delvigne AC, Thompson EW, Foidart JM and Birembaut P: Vimentin expression in cervical carcinomas: association with invasive and migratory potential. J Pathol 180(2): 175-180, 1996.
12. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP and Sauter G: Highthroughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154(4): 981-986, 1999.
13. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, Villette JM, Stower MJ and Maitland NJ: Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 52(4): 253-263, 2002.
14. Heatley MK, Ewings P, Odling Smee W, Maxwell P and Toner PG: Vimentin expression does not assist in predicting survival in ductal carcinoma of the breast. Pathology 34(3): 230-232, 2002.
15. Kiyasu Y, Kaneshima S and Koga S: Morphogenesis of peritoneal metastasis in human gastric cancer. Cancer Res 41(3): 1236-1239, 1981.
16. Tahara E: Growth factors and oncogenes in human gastrointestinal carcinomas. J Cancer Res Clin Oncol 116(2): 121-131, 1990. (Pubitemid 20271913)
17. Maruyama M, Sasaki T and Kubota H: Endoscopic treatment of early cancer of the large bowel. Gan No Rinsho 32(10): 1309-1316, 1986.
18. Grunert S, Jechlinger M and Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4(8): 657-665, 2003.
19. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H and Grunert S: Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 156(2): 299-313, 2002.
20. Kinugasa S, Abe S, Tachibana M, Hishikawa Y, Yoshimura H, Monden N, Dhar DK, Nagasue N and Nagaoka S: Overexpression of transforming growth factor-betal in scirrhous carcinoma of the stomach correlates with decreased survival. Oncology 55(6): 582-587, 1998.
21. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M and Kaibara N: An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 20(65): 4489-4493, 2000.
22. Massague J: TGFbeta in Cancer. Cell 134(2): 215-230, 2008.
23. Yang L and Moses HL: Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res 65(22): 9107-9111, 2008.
24. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL and Moses HL: Transforming growth factorbetal mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12(1): 27-36, 2001.